Regeneron Pharmaceuticals, Inc. (REGN) stock price, news and key stats

Price

Last close as of Sep 16, 2026. Delayed data; not a live quote.

Previous close

$774.11

Open

$775.82

Day range

$771.80 – $779.98

Volume

382K

About Regeneron Pharmaceuticals, Inc.

Latest REGN news

• The benefits of next-generation peptides will be thinly spread
  FT Companies · Sep 9, 2026

  Next-generation peptides, which have garnered attention for their potential in various therapeutic applications, are likely to face challenges in widespread adoption due to their cost and consumer price sensitivity. A recent survey indicates that pricing is a significant factor influencing consumer decisions, with many opting to discontinue use when faced with rising costs. This trend suggests that while the scientific advancements in peptide technology may be promising, their market penetration could be limited if manufacturers do not address affordability. The implications for the peptide market are considerable. As companies strive to innovate and differentiate their products, they may need to balance the costs of research and development with the price points that consumers are willing to accept. If manufacturers cannot find a way to produce these next-generation peptides at a lower cost, the benefits of their advancements may be "thinly spread" across a limited consumer base. This could lead to a fragmented market where only a few players succeed, while others struggle to maintain profitability in a price-sensitive environment. Investors and stakeholders should monitor how pricing strategies evolve in response to consumer behavior, as this will be crucial for the future of peptide therapeutics.

• Evaluating Bullish Potential in Regeneron Pharmaceuticals (REGN) Stock
  Yahoo Finance · Sep 8, 2026

  Regeneron Pharmaceuticals, Inc. (REGN) has shown resilience in the biotechnology sector, maintaining a "Buy" rating from analysts despite recent share price fluctuations and underperformance relative to the S&P 500. The company's strong revenue drivers, particularly its flagship products Dupixent and Libtayo, continue to support a positive outlook. Dupixent, in particular, has seen expanding indications, which bodes well for future growth and revenue generation. However, the stock has faced challenges, including a significant drop of nearly 10% following a securities fraud class action lawsuit alleging that Regeneron misled investors about the success of its products. This legal issue, coupled with a recent unfavorable ruling from a U.S. Federal judge, has contributed to investor uncertainty. Despite these setbacks, analysts remain cautiously optimistic about Regeneron's long-term potential, suggesting that the company's innovative pipeline and market position could ultimately drive recovery and growth in the stock. As the market evaluates these developments, investors will be closely watching how Regeneron navigates these challenges and capitalizes on its existing strengths.

• Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff
  MarketWatch · Sep 8, 2026

  Shares of Novartis plummeted over 3% on Monday following the disappointing results of a pivotal trial for its cholesterol drug, which aimed to lower lipoprotein(a) or Lp(a) levels to reduce cardiovascular risks. The failure of this trial not only undermines Novartis's strategy but also raises concerns about the broader viability of Lp(a) targeting therapies in the biopharmaceutical sector. Investors had anticipated significant advancements in this area, making the trial results particularly impactful. The fallout from Novartis's announcement extended beyond its own stock, triggering a selloff across the biopharma industry as market participants reevaluated the potential of similar treatments from other companies. The collective market response reflects a growing skepticism towards the efficacy of Lp(a) lowering strategies, which had garnered considerable attention and investment. Analysts suggest that this could lead to a reevaluation of research and development priorities within the sector, as companies may now face increased pressure to demonstrate the viability of their cardiovascular drug pipelines.

• SEC, FDA Enter Info-Sharing Pact To Bolster Enforcement
  Financial Regulation · Sep 1, 2026

  The U.S. Securities and Exchange Commission (SEC) and the Food and Drug Administration (FDA) have announced a new information-sharing agreement aimed at enhancing enforcement capabilities across both agencies. This collaboration is designed to improve oversight of companies that operate in both the financial and healthcare sectors, particularly those involved in the development and marketing of pharmaceuticals and medical devices. By sharing data and insights, the agencies hope to better identify potential violations of securities laws and regulations related to misleading claims or fraudulent activities. This partnership comes at a time when regulatory scrutiny is intensifying, particularly in industries where financial and health-related interests intersect. The SEC has been increasingly focused on ensuring that companies provide accurate disclosures about their products and financial health, especially in light of recent high-profile cases of alleged fraud in the biotech sector. The FDA, on the other hand, has been under pressure to ensure that drug and device approvals are not influenced by misleading financial information. Market implications of this agreement could be significant, as companies may face heightened scrutiny regarding their financial disclosures and marketing practices. Investors may need to reassess the risk profiles of firms operating in these dual-regulated spaces, particularly those with a history of aggressive financial reporting or regulatory challenges. Overall, this collaboration signals a proactive approach by U.S. regulators to safeguard both investors and public health.

• Regeneron Pharmaceuticals (REGN) Adjusts Course Amid Mixed Results in Melanoma Drug Trials
  Yahoo Finance · Aug 27, 2026

  Regeneron Pharmaceuticals (NASDAQ: REGN) is navigating turbulent waters following mixed results from its Phase 3 clinical trials for a new melanoma treatment, which has prompted the company to adjust its strategic focus. The trials, which were anticipated to bolster Regeneron's portfolio in oncology, yielded results that fell short of expectations, leading to investor concerns about the drug's efficacy and market potential. As a result, the company is now reevaluating its development plans and may shift resources toward more promising therapeutic areas. The implications for Regeneron’s stock are significant, as the disappointing trial outcomes have already sparked a securities class action lawsuit from investors who feel misled about the drug's prospects. This legal challenge could further strain investor confidence and impact the company's market valuation in the near term. Analysts are closely monitoring the situation, as the outcome of the lawsuit and the company's subsequent strategic decisions will likely influence its stock performance and overall market position in the competitive biopharmaceutical landscape.

• FAQ: The Strategic and Regulatory Logic Behind Biopharma M&A, From Deal Pricing to IND Sponsorship
  IPO & M&A · Aug 26, 2026

  The biopharmaceutical sector has witnessed a surge in mergers and acquisitions (M&A) activity, driven by a combination of strategic imperatives and regulatory considerations. Companies are increasingly looking to consolidate their portfolios to enhance research capabilities, expand market access, and accelerate the development of innovative therapies. Deal pricing has become a critical factor, with valuations often reflecting not only the current pipeline potential but also the anticipated regulatory hurdles and market dynamics. Regulatory frameworks play a significant role in shaping M&A strategies within the biopharma industry. The process of Investigational New Drug (IND) sponsorship is a key consideration for companies evaluating potential acquisitions. Firms are keenly aware that the ability to navigate the complex regulatory landscape can significantly impact the success of drug development and commercialization. As a result, acquiring companies often seek targets with established regulatory pathways or promising candidates that align with their strategic goals. Market implications of these trends are profound. Increased consolidation can lead to reduced competition, potentially impacting drug pricing and availability. Conversely, successful mergers can result in enhanced innovation, as combined resources may lead to more robust R&D efforts. Investors are closely monitoring these developments, as the outcomes of biopharma M&A activity will likely influence stock valuations and the overall health of the sector in the coming years.

• Your Questions Answered: Emerging Trends in Pharma Funding and M&A
  IPO & M&A · Aug 17, 2026

  The pharmaceutical sector is witnessing a significant shift in funding and merger and acquisition (M&A) activity, particularly in the biotech space. Recent trends indicate a robust influx of capital directed toward clinical-stage and platform biotech companies, driven by heightened investor interest in innovative therapies, especially in oncology and rare diseases. This surge is marked by an increase in partnerships and public offerings, as companies seek to leverage their unique capabilities and accelerate the development of groundbreaking treatments. Market analysts suggest that this trend is likely to continue, as the demand for novel therapies grows alongside an aging population and rising healthcare costs. The favorable funding environment is further bolstered by the success of recent IPOs, which have provided a blueprint for emerging companies to attract investment. Additionally, larger pharmaceutical firms are increasingly looking to acquire smaller biotech firms to bolster their pipelines, particularly in high-growth areas, thereby intensifying competition in the marketplace. As the landscape evolves, stakeholders should remain vigilant about the implications of these trends. The ongoing consolidation within the industry may lead to fewer players but could also foster innovation as companies combine resources and expertise. Investors are advised to monitor developments closely, as the dynamics of funding and M&A will likely shape the future of the pharmaceutical industry, influencing stock valuations and strategic positioning across the sector.

• In-vivo Prime Editing Platform Market Outlook Highlights Strategic Opportunities Across The Industry
  Market Outlook · Aug 13, 2026

  The in-vivo prime editing platform market is poised for significant growth, driven by advancements in gene editing technologies and increasing investment in biotechnology research. As the demand for precise genetic modifications rises, the market is expected to expand rapidly, with strategic opportunities emerging for companies that innovate in this space. Analysts project that the market could reach a valuation of several billion dollars within the next five years, fueled by applications in therapeutic development, agriculture, and genetic research. Key players in the industry are focusing on collaborations and partnerships to enhance their capabilities and broaden their product offerings. This trend is likely to lead to a surge in mergers and acquisitions as companies seek to consolidate their positions and leverage complementary technologies. Moreover, regulatory advancements and growing acceptance of gene editing in clinical settings are expected to further accelerate market growth. Investors are advised to closely monitor developments in this sector, as breakthroughs in prime editing could reshape therapeutic approaches to genetic disorders and other diseases, presenting lucrative opportunities for early adopters.

• July healthcare recap: Regeneron, DexCom shine as Moderna, managed-care stocks retreat
  Seeking Alpha · Aug 1, 2026

  In July, the healthcare sector experienced a mixed performance, highlighted by strong gains from Regeneron Pharmaceuticals and DexCom, while Moderna and various managed-care stocks faced declines. Regeneron saw a notable increase in its stock price, driven by positive clinical trial results and robust sales of its flagship products. Similarly, DexCom benefited from rising demand for its continuous glucose monitoring systems, which are increasingly being adopted by diabetes patients and healthcare providers alike. Conversely, Moderna's stock retreated amid concerns over diminishing demand for its COVID-19 vaccine as the pandemic's urgency wanes. The company is now pivoting towards developing new vaccines and therapies, but investor sentiment has been cautious. Managed-care stocks also struggled, reflecting broader concerns about potential regulatory changes and rising costs associated with healthcare services. The contrasting performances within the sector underscore the ongoing volatility and shifting dynamics in healthcare investments, suggesting that investors may need to remain selective in their stock picks moving forward.

• Eli Lilly, Regeneron named to FDA pilot program to boost US drug manufacturing
  Seeking Alpha · Jun 29, 2026

  Eli Lilly and Regeneron Pharmaceuticals have been selected to participate in a new pilot program initiated by the U.S. Food and Drug Administration (FDA) aimed at enhancing domestic drug manufacturing capabilities. This initiative is part of a broader effort to ensure a more resilient pharmaceutical supply chain, particularly in light of disruptions experienced during the COVID-19 pandemic. The FDA's program will focus on streamlining regulatory processes and providing support to companies that invest in U.S.-based manufacturing facilities. The inclusion of these two major pharmaceutical companies in the pilot program underscores the government's commitment to bolstering local production of essential medications. Analysts suggest that this move could lead to increased investment in manufacturing infrastructure, potentially resulting in job creation and economic growth within the sector. Furthermore, by fostering a more robust domestic supply chain, the FDA aims to mitigate risks associated with reliance on overseas production, which has been a concern for many stakeholders. Market implications of this initiative may be significant, as companies that successfully navigate the pilot program could gain a competitive edge in the pharmaceutical landscape. Investors may view Eli Lilly and Regeneron favorably, anticipating that enhanced manufacturing capabilities could lead to improved product availability and potentially lower costs. As the program progresses, it will be crucial to monitor how these developments influence the broader market dynamics and the operational strategies of participating firms.

All 15 articles in the app →

Index membership

• S&P 500 · Health Care
• Nasdaq-100 · Health Care

Related Health Care stocks

• AAgilent Technologies
• ABBVAbbVie
• ABTAbbott Laboratories
• ALGNAlign Technology
• AMGNAmgen
• BAXBaxter International
• BDXBecton Dickinson
• BIIBBiogen